Fabio V Lima1, Luis Gruberg2, Usman Aslam3,4, Melissa Ramgadoo5, Kydanis Clase6, Alessandra Trevisan5,7, Allen Jeremias8. 1. Department of Medicine, Brown University Rhode Island Hospital, Providence, Rhode Island. 2. Department of Cardiology, Hofstra Northwell School of Medicine, Northwell Health, Southside Hospital, Bay Shore, New York. 3. Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 4. New York Institute of Technology, College of Osteopathic Medicine, Old Westbury, New York. 5. Department of Medicine, Division of Cardiovascular Diseases, Stony Brook University Medical Center, Stony Brook, New York. 6. Department of Surgery, Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, New York. 7. Graduate Program in Public Health, Stony Brook University, Stony Brook, New York. 8. Department of Medicine, Division of Cardiology, St. Francis Hospital, The Heart Hospital, Roslyn, New York.
Abstract
OBJECTIVES: To compare bleeding and clinical events of patients with stable angina or silent ischemia undergoing percutaneous coronary intervention (PCI) treated withunfractionated heparin (UFH) or bivalirudin. BACKGROUND: Few direct comparisons between UFH monotherapy versus bivalirudin exist for patients with stable ischemic heart disease undergoing PCI. METHODS: A prospective, investigator-initiated, single-center, single-blinded, randomized trial of UFH versus bivalirudin was conducted. The primary endpoint was all bleeding (major and minor) from index-hospitalization to 30 days post discharge. Secondary endpoints included major adverse cerebral and cardiovascular events (MACCE) and net adverse clinical events (NACE). RESULTS:Two-hundred-sixty patients were randomized for treatment with either UFH (n = 123) (47%) or bivalirudin (n = 137) (53%) There were no significant differences in baseline clinical and angiographic characteristics between the two groups. Primary endpoint was similar in both groups (10.9% with bivalirudin vs 7.3% with UFH [P = 0.31]). Major bleeding rates were 5.8% and 2.4%, respectively (P = 0.17). There was a higher MACCE (3.5% vs 0%, P = 0.03) and NACE (8.8% vs 2.4%, P = 0.03) rate with bivalirudin compared to UFH, respectively. Bivalirudin had increased odds of NACE (OR = 3.65, 95% CI: 1.00-13.3.6). Death and stent thrombosis rates were low and similar in both groups. Radial access was associated with fewer bleeding events compared to femoral access but not statistically significant (P = 0.29). CONCLUSIONS: Among patients with stable angina or silent ischemia, there was no difference between UFH and bivalirudin in bleeding rates up to 30-days post-PCI. MACCE and NACE were higher among the bivalirudin group. Radial access was associated with a numerically lower rate of bleeding compared with femoral access.
RCT Entities:
OBJECTIVES: To compare bleeding and clinical events of patients with stable angina or silent ischemia undergoing percutaneous coronary intervention (PCI) treated with unfractionated heparin (UFH) or bivalirudin. BACKGROUND: Few direct comparisons between UFH monotherapy versus bivalirudin exist for patients with stable ischemic heart disease undergoing PCI. METHODS: A prospective, investigator-initiated, single-center, single-blinded, randomized trial of UFH versus bivalirudin was conducted. The primary endpoint was all bleeding (major and minor) from index-hospitalization to 30 days post discharge. Secondary endpoints included major adverse cerebral and cardiovascular events (MACCE) and net adverse clinical events (NACE). RESULTS: Two-hundred-sixty patients were randomized for treatment with either UFH (n = 123) (47%) or bivalirudin (n = 137) (53%) There were no significant differences in baseline clinical and angiographic characteristics between the two groups. Primary endpoint was similar in both groups (10.9% with bivalirudin vs 7.3% with UFH [P = 0.31]). Major bleeding rates were 5.8% and 2.4%, respectively (P = 0.17). There was a higher MACCE (3.5% vs 0%, P = 0.03) and NACE (8.8% vs 2.4%, P = 0.03) rate with bivalirudin compared to UFH, respectively. Bivalirudin had increased odds of NACE (OR = 3.65, 95% CI: 1.00-13.3.6). Death and stent thrombosis rates were low and similar in both groups. Radial access was associated with fewer bleeding events compared to femoral access but not statistically significant (P = 0.29). CONCLUSIONS: Among patients with stable angina or silent ischemia, there was no difference between UFH and bivalirudin in bleeding rates up to 30-days post-PCI. MACCE and NACE were higher among the bivalirudin group. Radial access was associated with a numerically lower rate of bleeding compared with femoral access.
Authors: Glenn N Levine; Eric R Bates; James C Blankenship; Steven R Bailey; John A Bittl; Bojan Cercek; Charles E Chambers; Stephen G Ellis; Robert A Guyton; Steven M Hollenberg; Umesh N Khot; Richard A Lange; Laura Mauri; Roxana Mehran; Issam D Moussa; Debabrata Mukherjee; Brahmajee K Nallamothu; Henry H Ting Journal: Circulation Date: 2011-11-07 Impact factor: 29.690
Authors: Sidney C Smith; Ted E Feldman; John W Hirshfeld; Alice K Jacobs; Morton J Kern; Spencer B King; Douglass A Morrison; William W O'Neil; Hartzell V Schaff; Patrick L Whitlow; David O Williams; Elliott M Antman; Cynthia D Adams; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Sharon Ann Hunt; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel Journal: Circulation Date: 2006-02-21 Impact factor: 29.690
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Martial Hamon; Pierre Coste; Arnoud Van't Hof; Jurrien Ten Berg; Peter Clemmensen; Xavier Tabone; Hakim Benamer; Steen D Kristensen; Claudio Cavallini; Antonio Marzocchi; Christian Hamm; Vojko Kanic; Debra Bernstein; Prodromos Anthopoulos; Efthymios N Deliargyris; Philippe Gabriel Steg Journal: Circ Cardiovasc Interv Date: 2015-06 Impact factor: 6.546
Authors: Ph Gabriel Steg; Stefan K James; Dan Atar; Luigi P Badano; Carina Blömstrom-Lundqvist; Michael A Borger; Carlo Di Mario; Kenneth Dickstein; Gregory Ducrocq; Francisco Fernandez-Aviles; Anthony H Gershlick; Pantaleo Giannuzzi; Sigrun Halvorsen; Kurt Huber; Peter Juni; Adnan Kastrati; Juhani Knuuti; Mattie J Lenzen; Kenneth W Mahaffey; Marco Valgimigli; Arnoud van 't Hof; Petr Widimsky; Doron Zahger Journal: Eur Heart J Date: 2012-08-24 Impact factor: 29.983
Authors: A Michael Lincoff; John A Bittl; Robert A Harrington; Frederick Feit; Neal S Kleiman; J Daniel Jackman; Ian J Sarembock; David J Cohen; Douglas Spriggs; Ramin Ebrahimi; Gadi Keren; Jeffrey Carr; Eric A Cohen; Amadeo Betriu; Walter Desmet; Dean J Kereiakes; Wolfgang Rutsch; Robert G Wilcox; Pim J de Feyter; Alec Vahanian; Eric J Topol Journal: JAMA Date: 2003-02-19 Impact factor: 56.272
Authors: Adeel Shahzad; Ian Kemp; Christine Mars; Keith Wilson; Claire Roome; Rob Cooper; Mohammed Andron; Clare Appleby; Mike Fisher; Aleem Khand; Babu Kunadian; Joseph D Mills; John L Morris; William L Morrison; Shahzad Munir; Nick D Palmer; Raphael A Perry; David R Ramsdale; Periaswamy Velavan; Rod H Stables Journal: Lancet Date: 2014-07-04 Impact factor: 79.321
Authors: Giuseppe Patti; Vincenzo Pasceri; Luca D'Antonio; Andrea D'Ambrosio; Michele Macrì; Giordano Dicuonzo; Giuseppe Colonna; Antonio Montinaro; Germano Di Sciascio Journal: Am J Cardiol Date: 2012-05-12 Impact factor: 2.778